Fig. 5

MCPs-EVs improve cavernous endothelial cell, pericytes, and neuronal cell content through miR-148a-3p in STZ-induced diabetic mice. a CD31 (green) and NG2 (red) immunostaining in cavernous tissue from age-matched nondiabetic controls, diabetic mice stimulated at 2 weeks after intracavernous PBS, MCPs-EVs-reagent control (MCPs-EVs-RC, 5 μg/20 μL), or MCPs-EVs-miR-148a-3p inhibitor (MCPs-EVs-miR-148a-3p-i, 5 μg/20 μL) injection; scale bar = 100 μm. b β (III)-tubulin (red) and nNOS (green) immunostaining in the same cavernous tissue section with the abovementioned CD31 staining groups; scale bar = 25 μm. Nuclear were labeled with DAPI (blue). c-f Quantitative analysis of cavernous endothelial cell, pericytes, and β (III)-tubulin- or nNOS-expressing neuronal cell contents using Image J. Data in graphs are presented as mean ± SEM (n = 4). The value expressed as ratios of the control group was set to 1. **p < 0.01; ***p < 0.001. STZ, streptozotocin; MCPs, mouse corpus cavernous pericytes; DAPI = 4,6-diamidino-2-phenylindole; ns, not significant